Guo Liang, Hamre John, Eldridge Sandy, Behrsing Holger P, Cutuli Facundo M, Mussio Jodie, Davis Myrtle
Laboratory of Investigative Toxicology, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland 21702.
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892.
Toxicol Sci. 2017 Mar 1;156(1):275-288. doi: 10.1093/toxsci/kfw254.
Chemotherapy-induced peripheral neuropathy (CIPN) is a major, dose-limiting adverse effect experienced by cancer patients. Advancements in mechanism-based risk mitigation and effective treatments for CIPN can be aided by suitable in vitro assays. To this end, we developed a multiparametric morphology-centered rat dorsal root ganglion (DRG) assay. Morphologic alterations in subcellular structures of neurons and non-neurons were analyzed with an automated microscopy system. Stains for NeuN (a neuron-specific nuclear protein) and Tuj-1 (β-III tubulin) were used to identify neuronal cell nuclei and neuronal cell bodies/neurites, respectively. Vimentin staining (a component of Schwann cell intermediate filaments) was used to label non-neuronal supporting cells. Nuclei that stained with DAPI, but lacked NeuN represented non-neuronal cells. Images were analyzed following 24 h of continuous exposure to CIPN-inducing agents and 72 h after drug removal to provide a dynamic measure of recovery from initial drug effects. Treatment with bortezomib, cisplatin, eribulin, paclitaxel or vincristine induced a dose-dependent loss of neurite/process areas, mimicking the 'dying back' degeneration of axons, a histopathological hallmark of clinical CIPN in vivo. The IC50 for neurite loss was within 3-fold of the maximal clinical exposure (Cmax) for all five CIPN-inducing drugs, but was >4- or ≥ 28-fold of the Cmax for 2 non-CIPN-inducing agents. Compound-specific effects, eg, neurite fragmentation by cisplatin or bortezomib and enlarged neuronal cell bodies by paclitaxel, were also observed. Collectively, these results support the use of a quantitative, morphologic evaluation and a DRG cell culture model to inform risk and examine mechanisms of CIPN.
化疗引起的周围神经病变(CIPN)是癌症患者面临的一种主要的剂量限制性不良反应。基于机制的风险缓解措施以及CIPN有效治疗方法的进展可借助合适的体外试验得到推动。为此,我们开发了一种以多参数形态学为中心的大鼠背根神经节(DRG)试验。使用自动显微镜系统分析神经元和非神经元亚细胞结构的形态学改变。分别使用NeuN(一种神经元特异性核蛋白)和Tuj-1(β-III微管蛋白)染色来识别神经元细胞核和神经元细胞体/神经突。波形蛋白染色(雪旺细胞中间丝的一个组成部分)用于标记非神经元支持细胞。用4',6-二脒基-2-苯基吲哚(DAPI)染色但缺乏NeuN的细胞核代表非神经元细胞。在连续暴露于CIPN诱导剂24小时后以及药物去除72小时后对图像进行分析,以提供从初始药物效应恢复的动态测量。用硼替佐米、顺铂、艾瑞布林、紫杉醇或长春新碱治疗会导致神经突/突起区域剂量依赖性丧失,模拟轴突的“逆行性”退化,这是体内临床CIPN的组织病理学特征。所有五种CIPN诱导药物的神经突丧失半数抑制浓度(IC50)在最大临床暴露量(Cmax)的3倍以内,但对于两种非CIPN诱导剂,IC50大于Cmax的4倍或≥28倍。还观察到了化合物特异性效应,例如顺铂或硼替佐米导致的神经突断裂以及紫杉醇导致的神经元细胞体增大。总体而言,这些结果支持使用定量形态学评估和DRG细胞培养模型来评估风险并研究CIPN的机制。